(Q36120794)

12 August 2017

1 reference

title

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors (English)

1 reference

12 August 2017

Peter M Fischer

1

1 reference

12 August 2017

Athos Gianella-Borradori

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

457-477

1 reference

CDK inhibitors in clinical development for the treatment of cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin dependent kinase 11 in RNA transcription and splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mouse development and cell proliferation in the absence of D-cyclins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin D-dependent kinases, INK4 inhibitors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin E ablation in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cdk2 knockout mice are viable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Do cells need CDK2 and ... Bcr-Abl?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Intra-S-phase checkpoint activation by direct CDK2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Abnormal expression pattern of cyclin E in tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Proliferation of cancer cells despite CDK2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Distinct roles for cyclin-dependent kinases in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Regulation of transcription elongation by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

21 January 2018

Fifty years of amanitin

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mechanism of action of dichloro-beta-D-ribofuranosylbenzimidazole: effect on in vitro transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-immobilized matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Drug-induced dispersal of transcribed rRNA genes and transcriptional products: immunolocalization and silver staining of different nucleolar components in rat cells treated with 5,6-dichloro-beta-D-ribofuranosylbenzimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mantle cell lymphoma: Therapeutic strategies are different from CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Mechanisms of action of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Phase II study of flavopiridol in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic cata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Advances in protein kinase B signalling: AKTion on multiple fronts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Indisulam: an anticancer sulfonamide in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Polo-like kinases and the orchestration of cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Tyrosine kinases as targets in cancer therapy - successes and failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

A new series of potent oxindole inhibitors of CDK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Synthesis of potent oxindole CDK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Cell death by mitotic catastrophe: a molecular definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Synthesis, Structure−Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Retraction Note: TGFβ1 activates c-Jun and Erk1 via aVβ6 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Surgeons as an Integral Part of the Cancer Research Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Protein kinases as targets for anti-parasitic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

Bioluminescent imaging of Cdk2 inhibition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.457

10.1517/13543784.14.4.457

21 January 2018

Identifiers

DOI

1 reference

release_pfgtikzzxragnoi4gehvofj4ge

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pfgtikzzxragnoi4gehvofj4ge

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference